Javelin Pharmaceuticals, a specialty pharma in the pain management sphere, has received an acquisition bid from Discus, a subsidiary of Hospira, leading Javelin to cancel its previous merger agreement with Myriad Pharmaceuticals. The move triggers a $4.4 million termination fee, which Hospira will pay. Hospira will pay $2.20 per share of Javelin, a 60% premium from Javelin’s previous share price, for a total of $141 million for all outstanding shares. Javelin will also be able to borrow...